

- study evaluating lateral branch radiofrequency denervation for sacroiliac joint pain. *Anesthesiology* 2008;109(2):279–88.
25. King W, Ahmed SU, Baisden J, et al. Diagnosis and treatment of posterior sacroiliac complex pain: A systematic review with comprehensive analysis of the published data. *Pain Med* 2015;16(2):257–65.
 26. Choi W-J, Hwang S-J, Song J-G, et al. Radiofrequency treatment relieves chronic knee osteoarthritis pain: A double-blind randomized controlled trial. *Pain* 2011;152(3):481–7.
 27. McCormick ZL, Korn M, Reddy R, et al. Cooled radiofrequency ablation of the genicular nerves for chronic pain due to knee osteoarthritis: Six-month outcomes. *Pain Med* 2017;18(9):1631–41.
 28. Davis T, Loudermilk E, DePalma M, et al. Prospective, multicenter, randomized, crossover clinical trial comparing the safety and effectiveness of cooled radiofrequency ablation with corticosteroid injection in the management of knee pain from osteoarthritis. *Reg Anesth Pain Med* 2018;43:84–91.
 29. Tran J, Peng PWH, Lam K, et al. Anatomical study of the innervation of anterior knee joint capsule: Implication for image-guided intervention. *Reg Anesth Pain Med* 2018;43(4):407–14.
 30. Fonkoue L, Behets CW, Steyaert A, et al. Accuracy of fluoroscopic-guided genicular nerve blockade: A need for revisiting anatomical landmarks. *Reg Anesth Pain Med* 2019;44(10):950–8.
 31. Conger A, Cushman DM, Walker K, et al. A novel technical protocol for improved capture of the genicular nerves by radiofrequency ablation. *Pain Med* 2019;20(11):2208–12.
 32. McCormick ZL, Cohen SP, Walega DR, Kohan L. Technical considerations for genicular nerve radiofrequency ablation: Optimizing outcomes. *Reg Anesth Pain Med* 2021;46(6):518–23.
 33. Koshi E, Cheney CW, Sperry BP, et al. Genicular nerve radiofrequency ablation for chronic knee pain using a three-tined electrode: A technical description and case series. *Pain Med* 2020;21(12):3344–49.
 34. Chen Y, vu TN, Chinchilli V. Clinical and technical factors associated with knee radiofrequency ablation outcomes: A multicenter analysis. *Regional Anesth Pain Med* 2021;46(4):298–304.
 35. Eckmann MS, Bickelhaupt B, FehJ, et al. Cadaveric study of the articular branches of the shoulder joint. *Reg Anesth Pain Med* 2017;42(5):564–70.
 36. Tran J, Peng PWH, Agur AMR. Anatomical study of the innervation of glenohumeral and acromioclavicular joint capsules: Implications for image-guided intervention. *Reg Anesth Pain Med* 2019;rapm-2018-100152.
 37. Birnbaum K, Prescher A, Hessler S, et al. The sensory innervation of the hip joint: An anatomical study. *Surg Radio Anat* 1997;19(6):371–5.
 38. Short AJ, Barnett JJG, Gofeld M, et al. Anatomic study of innervation of the anterior hip capsule: Implication for image-guided intervention. *Reg Anesth Pain Med* 2018;43(2):186–92.
 39. Eckmann MS, Johal J, Bickelhaupt B, et al. Terminal sensory articular nerve radiofrequency ablation for the treatment of chronic intractable shoulder pain: A novel technique and case series. *Pain Med* 2020;21(4):868–71.
 40. Kapural L. Cooled radiofrequency neurotomy of the articular sensory branches of the obturator and femoral nerves—combined approach using fluoroscopy and ultrasound guidance: Technical report, and observational study on safety and efficacy. *Pain Physician* 2018;1(21;1):279–84.
 41. Brown MF, Hukkanen MV, McCarthy ID, et al. Sensory and sympathetic innervation of the vertebral endplate in patients with degenerative disc disease. *J Bone Joint Surg Br* 1997;79(1):147–53.
 42. Frasc C, Kravetz P, Mody DR, Heggeness MH. Substance P-containing nerves within the human vertebral body: An immunohistochemical study of the basivertebral nerve. *Spine J* 2003;3(1):63–7.
 43. Becker S, Hadjipavlou A, Heggeness MH. Ablation of the basivertebral nerve for treatment of back pain: A clinical study. *Spine J* 2017;17(2):218–23.
 44. Conger A, Schuster NM, Cheng DS, et al. The effectiveness of intraosseous basivertebral nerve radiofrequency neurotomy for the treatment of chronic low back pain in patients with modic changes: A systematic review. *Pain Med* 2021;22(5):1039–54.

Pain Medicine, 22(7), 2021, 1467–1469

doi: 10.1093/pm/pnaa422

Advance Access Publication Date: 14 December 2020

Editorial



The Human Gut Microbiome and Its Relationship with Osteoarthritis Pain

Silvia Turrone, PhD,* Paolo Pedersini, MSc,[†] and Jorge Hugo Villafañe, PhD[†]

*University of Bologna, Bologna, Italy; [†]IRCCS Fondazione Don Carlo Gnocchi, Milan, Italy

Conflicts of interest: There are no conflicts of interest to report.

Key Words: Osteoarthritis; Microbiome; Pain

Editorial

The gut microbiome constitutes the largest reservoir of the human microbiome and probably the one most capable of influencing the health of the whole body through multiple system-level interactions. Composed mainly of bacteria but also fungi and viruses, this microbial ecosystem is highly diverse and complex, functionally redundant, individual specific, plastic, and resilient. An alteration of its structure, i.e., dysbiosis, has been shown to participate in the onset and progression of various metabolic and inflammatory diseases. This is mainly due to the increase of opportunistic pathogens or pathobionts and/or the depletion of health-associated taxa, such as short-chain fatty acid producers, with impaired intestinal permeability (i.e., leaky gut) and altered immune signaling [1]. It is therefore not surprising that the gut microbiome can also be a crucial factor in the management of osteoarthritis (OA). Exposure to stress and pain may lead to alterations in the interactions between the brain and the intestine (i.e., the gut–brain axis) by changing gastrointestinal secretion, gut motility and permeability, and microbial gene expression and quorum-sensing signals, thus contributing to dysbiosis and increasing the rate of translocation of bacterial products or even bacteria, thereby eliciting systemic inflammation [2] (Figure 1). It has been hypothesized that patients with OA-related pain will exhibit an imbalance of the gut microbiota associated with pain intensity [3].

Pain in OA cannot be attributed only to peripheral nociception, and modulation by nociceptive processing contributes to the pain experience. The discrepancies between pain in OA and the severity of radiographic

findings are usually associated with the propensity of some patients to show a sensitization phenotype and are supported by recent theories that OA involves complex mechanisms of altered pain transmission [4]. Pain in OA is related to innumerable internal and external factors, including environmental changes, diet, exercise, disease, stress, and genetics. A growing body of literature supports the importance of the brain–gut interaction in pain perception and points to the gut microbiota as a possible key factor in pain processing [5]. The microbiota may interfere with nociceptive signaling via various routes, including enteric and vagus neural communication and the endocrine and immune systems. In particular, the integrity of the intestinal barrier has been identified as an important checkpoint, which can allow the passage of microbial metabolites or vesicles presenting immunogenic epitopes, which can prime local and systemic macrophages, exacerbating joint inflammation and damage, thus leading to increased pain [6]. However, the current evidence is still limited, which emphasizes the need for large longitudinal cohort studies and mechanistic experiments in model systems. This will ideally lead to the identification of microbiome targets for the development of new microbiome-based precision strategies aimed at modulating pain pathways, thus optimizing peripheral manual and physical therapies for conservative nonpharmacological pain management in patients with OA.

In recent decades, the burden of OA has increased because of longer life expectancy but also because of the modern lifestyle, in particular physical inactivity and inadequate diets, which promote chronic low-grade inflammation and obesity. There is currently no gold standard




Figure 1. A triple gut–brain–joint microbiome axis. IL = interleukin; TNF = tumor necrosis factor.

method for treating patients with OA. Conservative non-pharmacological treatment has been shown to relieve symptoms in patients in early-stage OA disease and can stave off surgical interventions either temporarily or in the long term [7]. Applying a multimodal treatment that includes targeting of gut microbiota is a relatively new therapeutic strategy that can be easily applied by physicians in different clinical settings worldwide. Our hypothesis of gut microbiota involvement opens the way for future research on the modulation of pain pathways through the manipulation of microbial communities (e.g., by diet, pre- or probiotics, and physical activity), ultimately leading to practical targets to optimize pain management in OA. Emerging evidence suggests that alterations in nociceptive processing within the peripheral and/or central nervous system may be a key factor in accounting for variations in clinical presentations of pain associated with OA. Understanding the associations between OA and gut microbiota could lead to improved treatment approaches, greater therapeutic efficacy, and improved patient health.

References

- Schmidt TSB, Raes J, Bork P. The human gut microbiome: From association to modulation. *Cell* 2018;172(6):1198–215.
- Mukhtar K, Nawaz H, Abid S. Functional gastrointestinal disorders and gut–brain axis: What does the future hold? *World J Gastroenterol* 2019;25(5):552–66.
- Liu Y, Ding W, Wang HL, et al. Gut microbiota and obesity-associated osteoarthritis. *Osteoarthritis Cartilage* 2019;27(9):1257–65.
- Villafañe JH, Cleland JA, Fernandez-de-las-Peñas C. Bilateral sensory effects of unilateral passive accessory mobilization in patients with thumb carpometacarpal osteoarthritis. *J Manipulative Physiol Ther* 2013;36(4):232–7.
- Villafañe JH, Valdes K, Pedersini P, Berjano P. Osteoarthritis: A call for research on central pain mechanism and personalized prevention strategies. *Clin Rheumatol* 2019;38(2):583–4.
- Boer CG, Radjabzadeh D, Medina-Gomez C, et al. Intestinal microbiome composition and its relation to joint pain and inflammation. *Nat Commun* 2019;10(1):4881.
- Villafañe JH, Drago L. What is the site of pain osteoarthritis? A triple gut-brain-joint microbioma axis. *Clin Exp Rheumatol* 2019;37 Suppl 122(6):20–1.

PERSPECTIVE & COMMENTARY

Pain Medicine, 22(7), 2021, 1469–1472

doi: 10.1093/pm/pnaa274

Advance Access Publication Date: 8 November 2020

Commentary

OXFORD

Optimizing Acetaminophen Use in Patients with Risk Factors for Hepatotoxicity: Reviewing Dosing Recommendations in Adults

Deanna K. Bauerlein, PharmD, BCPS*[‡] Allison P. Williams[†] and Preeti R. John, MD, MPH, FACS, CPE, HEC-C^{†,‡}

*Veterans Affairs New Jersey Health Care System, East Orange, New Jersey; [†]University of Maryland School of Medicine, Baltimore, Maryland;

[‡]Veterans Affairs Maryland Health Care System, Baltimore, Maryland, USA

Introduction

Acetaminophen is the most commonly used analgesic and antipyretic in the United States, with more than 60 million Americans using the drug on a weekly basis [1]. In contrast to nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen is associated with fewer gastrointestinal, cardiovascular, and renal adverse drug events and drug interactions. The clearance of acetaminophen also does not change in relation to age, and thus acetaminophen is recommended by the American Geriatrics Society for chronic pain [2]. Following the opioid crisis and heightened awareness by the medical community of the need for multimodal analgesia, adjuncts to

opioids such as acetaminophen are being used more commonly to treat acute and chronic pain. Unfortunately, acetaminophen-induced hepatotoxicity resulting from unintentional overdose is the most common cause of acute liver failure in the United States, resulting in 30,000 hospital admissions per year [1]. It accounts for more than 50% of overdose-related acute liver failure and 20% of liver transplant cases [1]. Although adverse effects caused by acetaminophen represent a significant public health concern, the Food and Drug Administration's (FDA's) recommendations for maximum daily adult dosing have remained unchanged for decades, with no formal